Phathom shares fall after lawsuit against FDA over refusal to accept Voquezna ANDA
Phathom shares are falling after a lawsuit against the FDA, which refused to accept an ANDA for a generic version of Voquezna.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Phathom shares fell after a lawsuit was filed against the U.S. Food and Drug Administration (FDA) over its refusal to accept an ANDA for a generic version of Voquezna. The information comes from Seeking Alpha.
The report does not say how the dispute will develop or how it may affect the company's financial results.
why it matters
The story concerns a procedural dispute over a regulatory filing, so its market impact is mainly limited to Phathom's own shares rather than the broader market.
tags
instruments
sources
- Phathom falls as FDA sued over refusal to accept ANDA for generic Voquezna — Seeking Alpha, 23 October 2026 at 20:27 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗